%0 Journal Article
%T PD-1/PD-L1抑制剂在晚期胃癌治疗中的研究进展<br>Research Progress of PD-1/PD-L1 Inhibitors in the Treatment of Advanced Gastric Carcinoma
%A 李雨婷
%A 刘定定
%A 黄子静
%A 马雨琪
%A 杨卫卫
%J Advances in Clinical Medicine
%P 7108-7114
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.135993
%X 胃癌是我国常见的恶性肿瘤，传统化疗对晚期胃癌患者往往疗效有限。PD-1及其配体PD-L1是目前免疫治疗的研究热点。在肿瘤微环境中，肿瘤细胞表达大量PD-L1，PD-l与其配体结合后可抑制T细胞的功能，而PD-1/PD-L1抑制剂可重新激活效应T细胞，阻止肿瘤细胞逃逸。免疫单药治疗晚期胃癌已在临床中显示出显著疗效，但其联合用药模式是否将更好地改善患者预后尚未明确。期待未来深入研究PD-1/PD-L1抑制剂联合用药治疗晚期胃癌可使患者获益更多，包括化疗药物、抗血管生成药物及靶向药物等。<br />
The gastric carcinoma is a common malignant tumor in our country, and there is usually limited therapeutic effect on advanced gastric carcinoma treated by traditional chemotherapy. PD-1 and its ligand, PD-L1, have been the focus of immunotherapy research. In the tumor microenvironment, tumor cells express a large amount of PD-L1, and PD-l can inhibit the function of T cells after binding with its ligand, while PD-1/PD-L1 inhibitors can reactivate effector T cells and prevent the escape of tumor cells. Immunomonotherapy has shown significant clinical efficacy in the treatment of ad-vanced gastric carcinoma, but it is not clear whether its combination mode will better improve the prognosis of patients. It is expected that further studies on the combination of PD-1/PD-L1 inhibi-tors in the treatment of advanced gastric carcinomacan bring more benefits to patients, including chemotherapy drugs, anti-angiogenic drugs and targeted drugs.
%K PD-1，PD-L1，晚期胃癌，免疫检查点抑制剂<br>PD-1
%K PD-L1
%K Advanced Gastric Carcinoma
%K Immune Checkpoint Inhibitors
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=64985